<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03990467</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL17_0843</org_study_id>
    <nct_id>NCT03990467</nct_id>
  </id_info>
  <brief_title>Observed Pharmacokinetic of Piperacillin/Tazobactam Compared to Amikacin in ICU</brief_title>
  <acronym>OPTIMA</acronym>
  <official_title>Observed Pharmacokinetic of Piperacillin/Tazobactam in ICU Patients Compared to Therapeutic Drug Monitoring of Amikacin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The pharmacokinetics of antimicrobials is profoundly modified in Intensive care unit (ICU)&#xD;
      patients. To adapt the treatment, it is recommended to measure blood levels of antibiotics.&#xD;
      Some antibiotics, such as amikacin, are easy to monitor, while for other molecules, such as&#xD;
      piperacillin/tazobactam, the drug monitoring is more difficult to obtain. These two molecules&#xD;
      have similar physicochemical characteristics (hydrophilicity) and therefore have closed&#xD;
      pharmacokinetic properties. OPTIMA is a study aiming at criteria will be used to judge&#xD;
      whether the pharmacokinetic (PK) parameters of amikacin are predictive of those of&#xD;
      piperacillin and tazobactam.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 28, 2021</start_date>
  <completion_date type="Anticipated">January 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 28, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in plasma concentration of amikacin during the first 24 hours after administration</measure>
    <time_frame>First 24 hours of the antimicrobial treatment (Hour 1, Hour 5, Hour 7 and Hour 24)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in plasma concentration of piperacillin during the first 24 hours after administration</measure>
    <time_frame>First 24 hours of the antimicrobial treatment (Hour 1, Hour 5, Hour 7 and Hour 24)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in plasma concentration of tazobactam during the first 24 hours after administration</measure>
    <time_frame>First 24 hours of the antimicrobial treatment (Hour 1, Hour 5, Hour 7 and Hour 24)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose administered of amikacin at baseline</measure>
    <time_frame>Hour 0 (Baseline)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose administered of piperacillin at baseline</measure>
    <time_frame>Hour 0 (Baseline)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose administered of tazobactam at baseline</measure>
    <time_frame>Hour 0 (Baseline)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in plasma volume of distribution of amikacin during the first 24 hours after administration</measure>
    <time_frame>First 24 hours of the antimicrobial treatment (Hour 1, Hour 5, Hour 7 and Hour 24)</time_frame>
    <description>In order to evaluate whether the PK parameters of amikacin are predictive of those of piperacillin and tazobactam.&#xD;
Plasma volume of distribution is one of the two PK parameters evaluated in this study (with clearance), calculated with drug plasma concentration and dose administered</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in plasma volume of distribution of piperacillin during the first 24 hours after administration</measure>
    <time_frame>First 24 hours of the antimicrobial treatment (Hour 1, Hour 5, Hour 7 and Hour 24)</time_frame>
    <description>In order to evaluate whether the PK parameters of amikacin are predictive of those of piperacillin and tazobactam.&#xD;
Plasma volume of distribution is one of the two PK parameters evaluated in this study (with clearance), calculated with drug plasma concentration and dose administered</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in plasma volume of distribution of tazobactam during the first 24 hours after administration</measure>
    <time_frame>First 24 hours of the antimicrobial treatment (Hour 1, Hour 5, Hour 7 and Hour 24)</time_frame>
    <description>In order to evaluate whether the PK parameters of amikacin are predictive of those of piperacillin and tazobactam.&#xD;
Plasma volume of distribution is one of the two PK parameters evaluated in this study (with clearance), calculated with drug plasma concentration and dose administered</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in plasma clearance of amikacin during the first 24 hours after administration</measure>
    <time_frame>First 24 hours of the antimicrobial treatment (Hour 1, Hour 5, Hour 7 and Hour 24)</time_frame>
    <description>In order to evaluate whether the PK parameters of amikacin are predictive of those of piperacillin and tazobactam.&#xD;
Plasma clearance is one of the two PK parameters evaluated in this study (with volume of distribution), calculated with drug plasma concentration and dose administered</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in plasma clearance of piperacillin during the first 24 hours after administration</measure>
    <time_frame>First 24 hours of the antimicrobial treatment (Hour 1, Hour 5, Hour 7 and Hour 24)</time_frame>
    <description>In order to evaluate whether the PK parameters of amikacin are predictive of those of piperacillin and tazobactam.&#xD;
Plasma clearance is one of the two PK parameters evaluated in this study (with volume of distribution), calculated with drug plasma concentration and dose administered</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in plasma clearance of tazobactam during the first 24 hours after administration</measure>
    <time_frame>First 24 hours of the antimicrobial treatment (Hour 1, Hour 5, Hour 7 and Hour 24)</time_frame>
    <description>In order to evaluate whether the PK parameters of amikacin are predictive of those of piperacillin and tazobactam.&#xD;
Plasma clearance is one of the two PK parameters evaluated in this study (with volume of distribution), calculated with drug plasma concentration and dose administered</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Septic Shock</condition>
  <condition>Sepsis</condition>
  <condition>Sepsis Syndrome</condition>
  <arm_group>
    <arm_group_label>Patients treated by amikacin and piperacillin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ICU patient with a sepsis treated by amikacin and piperacillin/tazobactam</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Plasma dosage of amikacin, piperacillin and tazobactam</intervention_name>
    <description>Pharmacokinetic (PK) criteria will be used to judge whether the PK parameters of amikacin are predictive of those of piperacillin and tazobactam</description>
    <arm_group_label>Patients treated by amikacin and piperacillin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient â‰¥ 18 years old&#xD;
&#xD;
          -  Patient hospitalized in the critical care department of the Lyon-Sud hospital centre&#xD;
&#xD;
          -  Patient with a sepsis or a severe sepsis table defined by the latest international&#xD;
             recommendations&#xD;
&#xD;
          -  Patient to be treated by the amikacin + piperacillin/tazobactam association&#xD;
&#xD;
          -  Patient affiliated to a social security system, having agreed to participate in the&#xD;
             study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with a known history of hypersensitivity or contraindication to amikacin,&#xD;
             piperacillin or tazobactam&#xD;
&#xD;
          -  Patient known to have previously received piperacillin/tazobactam or amikacin&#xD;
             combination before inclusion&#xD;
&#xD;
          -  Patient treated at the time of inclusion with dialysis techniques&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Arnaud FRIGGERI, MD</last_name>
    <phone>478865647</phone>
    <phone_ext>+33</phone_ext>
    <email>arnaud.friggeri@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alain LEPAPE, MD</last_name>
    <phone>478861989</phone>
    <phone_ext>+33</phone_ext>
    <email>alain.lepape@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service d'AnesthÃ©sie et RÃ©animation - Secteur de Soins Critiques, Groupement Hospitalier Sud, HCL</name>
      <address>
        <city>Pierre-BÃ©nite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnaud FRIGGERI, MD</last_name>
      <phone>478865647</phone>
      <phone_ext>+33</phone_ext>
      <email>arnaud.friggeri@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Arnaud FRIGGERI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alain LEPAPE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernard ALLAOUCHICHE, MD, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien BOHE, MD, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manon MARIE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florent WALLET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivia VASSAL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 4, 2019</study_first_submitted>
  <study_first_submitted_qc>June 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2019</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Systemic Inflammatory Response Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Amikacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

